A study (71) found that NKX3.1 was absent in 20% of PIN lesions, 6% of low stage prostate tumors, 22% of high stage prostate tumors, 34% of androgen-independent tumors and 78% of prostate cancer metastases. This evidence concerns the gene NKX3-1 and prostate neoplasm.